Journal of Clinical Endocrinology & Metabolism, Vol 75, 879-885, Copyright © 1992 by Endocrine Society

ARTICLES

A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets

W Sullivan, T Carpenter, F Glorieux, R Travers and K Insogna
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510-8056.

Current treatment of X-linked hypophosphatemia (XLH) employs the combined administration of oral phosphate and 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. Although this drug regimen significantly improves the clinical course of the disease in children, the value of medical treatment in symptomatic adults with XLH has not been established. We, therefore, investigated the clinical, biochemical, and histological responses to phosphate and 1,25-(OH)2D3 in 16 symptomatic adult patients with XLH followed for a mean of 4.2 yr. Eighty-seven percent of the patients had an improvement in bone or joint pain with therapy. There was a significant increase in mean serum phosphate (from 0.61 +/- 0.03 to 0.77 +/- 0.03 mmol/L) and urinary calcium excretion (from 2.45 +/- 0.38 to 4.39 +/- 0.44 mmol/day) with treatment. Pretreatment bone biopsies demonstrated findings characteristic of osteomalacia, including abnormally increased osteoid volume and decreased mineral apposition rates. Treatment was accompanied by a significant decrease in osteoid thickness as well as a reduction in mean osteoid volume. However, therapy did not completely normalize these parameters. Disease severity, as assessed by histomorphometric parameters, did not correlate with any pretreatment serum or urinary biochemical measurement, but did seem to correlate with symptom score. Although most patients tolerated therapy without difficulty, 1 patient developed tertiary hyperparathyroidism during treatment and renal insufficiency that progressed despite cessation of therapy. This study provides evidence that therapy with oral phosphate and 1,25-(OH)2D3 in symptomatic adults with XLH can result in significant clinical and histomorphometric improvement.

This article has been cited by other articles:

				S. Liu, W. Tang, J. Zhou, J. R. Stubbs, Q. Luo, M. Pi, and L. D. Quarles Fibroblast Growth Factor 23 Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1305 - 1315. [Abstract] [Full Text] [PDF]

				R.J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T.J. Smith, K.J. McNeill, G. Jerums, X Bai, D. Miao, J. Li, D. Goltzman, et al. Type 2 Diabetes: Absence of Proteinuria Does Not Preclude Loss of Renal Function: Nonalbuminuric Renal Insufficiency in Type 2 Diabetes. Diabetes Care 27: 195-200, 2004 J. Am. Soc. Nephrol., February 1, 2005; 16(2): 284 - 290. [Full Text] [PDF]

				X. Bai, D. Miao, J. Li, D. Goltzman, and A. C. Karaplis Transgenic Mice Overexpressing Human Fibroblast Growth Factor 23 (R176Q) Delineate a Putative Role for Parathyroid Hormone in Renal Phosphate Wasting Disorders Endocrinology, November 1, 2004; 145(11): 5269 - 5279. [Abstract] [Full Text] [PDF]

				K. Sato, T. Obara, K. Yamazaki, M. Kanbe, K. Nakajima, A. Yamada, T. Yanagisawa, Y. Kato, T. Nishikawa, and K. Takano Somatic Mutations of the MEN1 Gene and Microsatellite Instability in a Case of Tertiary Hyperparathyroidism Occurring during High Phosphate Therapy for Acquired, Hypophosphatemic Osteomalacia J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5564 - 5571. [Abstract] [Full Text] [PDF]

				A. H. Zargar, B. A. Laway, S. R. Masoodi, F. A. Hakim, A. I. Wani, M. I. Bashir, and A. Mithal Hereditary hypophosphataemic rickets: report of a family from the Indian subcontinent Postgrad. Med. J., August 1, 1999; 75(886): 485 - 487. [Abstract] [Full Text]